PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
about
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesProstate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.Prostate Cancer Imaging with Novel PET Tracers.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?A Feasibility Study Showing [(68)Ga]Citrate PET Detects Prostate Cancer.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review.Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.Metal-Based PSMA Radioligands.Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational StudyDetection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T.Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary anaPerformance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.Analysis of Risk Factors for Lymphatic Metastasis in Endometrial Carcinoma and Utility of Three-Dimensional Magnetic Resonance Imaging in Gynecology.
P2860
Q28067404-FBDDA7E0-0706-4CE0-BC02-E4967D1F9E7EQ33914844-99F230B2-B69A-4F8E-BD31-87B0F954123AQ36632690-DAD32EDD-099B-405B-B998-F1AF9BDBE511Q36942136-B2D59CFC-8CF4-49D1-A6B2-A7C6E874728AQ36999897-3F82BCAB-837E-4BA8-94E4-D3787C8102A3Q38709405-BE644262-2B76-45DA-8E13-C2EB886B8C07Q38720852-71C252D3-B678-475F-B38B-CB3F9937C966Q38732369-73E09366-AF88-4A8D-B867-6659831F065DQ38747415-F6CF0DC0-00C3-4483-BE35-7B7B8FCB5DB6Q38800196-07687461-A8CF-4EC4-B63E-2EC5F877A12BQ38831232-F0BB4CA3-69E6-4E7E-8F7E-D01B5A0B715DQ38952552-365087DB-365D-4844-82E7-15601B9F7079Q38966705-8EE92CB1-1C5E-4C35-9648-A91103ECA605Q39143896-7820DBFA-2030-41A2-ADEA-709628353E21Q39198527-3A4F9226-3164-429F-8B7D-DB4415CD4BC9Q47101682-A191C0AB-71DB-4D02-AFD4-9CC09E9AA0F5Q47107456-A9B36616-8A26-4609-BE98-84FFA475BAB0Q47147617-9CCC5C68-BE0A-461C-AF2C-73D362E51DDCQ47805128-9A9E4E04-C040-45F0-B826-AF5A4D2201B9Q48116656-B69F3F54-8510-48A1-965F-D29BFEB49AD2Q48177983-1E020C0C-95E2-4BA6-B5BB-CB8C0ABD19AFQ48221776-EF71A34E-EA4C-450A-8FE1-4464ABD63AE4Q48226517-7A42F136-F9FA-4778-BE25-5124E02F8208Q48898788-A58901CC-9EE1-45BF-8A1B-04EA84E50B3AQ50182743-5C86D6CC-6D78-41F4-B86E-BBDDC57D209EQ51715242-3E650E2B-06EC-4F6E-8972-B7E4D869AE8CQ52940451-17C0DDD3-3670-42DD-95F4-528EA03A8BA8Q52983369-058106F7-0D46-4513-8197-5A315DF27F8CQ52984262-D2BE7AE0-1D68-484F-857F-AC12B45BE5AAQ55118858-86E94CC2-372C-40AC-BDF4-D106C9F82462Q55518937-F2165EE0-24C5-4AC2-9AB1-3303489DCB37
P2860
PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@ast
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@en
type
label
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@ast
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@en
prefLabel
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@ast
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@en
P2093
P2860
P1476
PSMA PET/CT with Glu-urea-Lys- ...... t in recurrent prostate cancer
@en
P2093
C Kratochwil
F Sterzing
Frederik L Giesel
M Stefanova
P L Choyke
U Haberkorn
P2860
P2888
P304
P356
10.1007/S00259-015-3106-6
P577
2015-07-11T00:00:00Z